203 related articles for article (PubMed ID: 26849508)
1. FDA approves three different multiple myeloma drugs in one month.
Ratner M
Nat Biotechnol; 2016 Feb; 34(2):126. PubMed ID: 26849508
[No Abstract] [Full Text] [Related]
2. Multiple Myeloma Gets Three New Drugs.
Poh A
Cancer Discov; 2016 Jan; 6(1):4. PubMed ID: 26658418
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma--translation of trial results into reality.
Moreau P; Rajkumar SV
Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
[No Abstract] [Full Text] [Related]
4. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
5. Therapy sequencing strategies in multiple myeloma: who, what and why?
Costello C; Mikhael JR
Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
[No Abstract] [Full Text] [Related]
6. Fairer way to distribute last-ditch drugs gets real-world trial.
Reardon S
Nature; 2016 Jun; 534(7606):160-1. PubMed ID: 27279187
[No Abstract] [Full Text] [Related]
7. Immunotherapy Combinations in Multiple Myeloma - Known Unknowns.
Gormley NJ; Pazdur R
N Engl J Med; 2018 Nov; 379(19):1791-1795. PubMed ID: 30403935
[No Abstract] [Full Text] [Related]
8. FDA panel votes to pull Avastin in breast cancer, again.
Ratner M
Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
[No Abstract] [Full Text] [Related]
9. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
10. How FDA approves biotechnology drugs.
Manuel SM; Piascik P
Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
[No Abstract] [Full Text] [Related]
11. Market watch: Upcoming catalysts in Q2 2015.
Burns J
Nat Rev Drug Discov; 2015 Apr; 14(4):228. PubMed ID: 25764988
[No Abstract] [Full Text] [Related]
12. The Ethical Challenges of Compassionate Use.
Caplan AL; Ray A
JAMA; 2016 Mar; 315(10):979-80. PubMed ID: 26868205
[No Abstract] [Full Text] [Related]
13. FDA approves new agent for multiple myeloma.
Fenichel MP
J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612
[No Abstract] [Full Text] [Related]
14. New Monoclonal Antibody Approved to Treat Multiple Myeloma.
Aschenbrenner DS
Am J Nurs; 2016 Mar; 116(3):22. PubMed ID: 26914046
[No Abstract] [Full Text] [Related]
15. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
16. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
17. EMEA approves OGS drug rejected by FDA.
Mitchell P
Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490
[No Abstract] [Full Text] [Related]
18. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
19. The FDA approves drugs for colorectal cancer, lung cancer.
FDA Consum; 2007; 41(1):5. PubMed ID: 17354284
[No Abstract] [Full Text] [Related]
20. Accelerated drug approval: FDA may get tougher; companies cite hurdles.
Goozner M
J Natl Cancer Inst; 2011 Mar; 103(6):455-7. PubMed ID: 21393609
[No Abstract] [Full Text] [Related]
[Next] [New Search]
